MAPT and Alzheimer disease: Both plasma pTau181 and tau PET discriminated with high accuracy between SCD Aβ-negative and SCD Aβ-positive individuals, but tau PET outperformed plasma pTau181 in discriminating cognitive stage (MCI/AD vs. SCD).